Gemcitabine and Docetaxel versus Doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue Sarcomas

http://isrctn.org/> ◽

10.1186/isrctn07742377 ◽

2013 ◽

Author(s):

Beatrice Seddon

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Adriamycin and Cis-Platinum as First-Line Treatment in Unresectable Locally Advanced or Metastatic Adult Soft-Tissue Sarcomas

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000071467.96942.2f ◽

2004 ◽

Vol 27 (3) ◽

pp. 307-311 ◽

Author(s):

Haralabos P. Kalofonos ◽

Dimitrios Bafaloukos ◽

Theodoros G. Kourelis ◽

Michalis V. Karamouzis ◽

Panagiotis Megas ◽

...

Keyword(s):

Soft Tissue ◽

Locally Advanced ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Randomized, Open, Prospective, Phase II Clinical Trial of Doxorubicin (DOXO) vs. Trabectedin Plus Doxo in the First-Line Treatment of Patients (PTS) with Advanced Non-Operable and/or Metastatic Soft Tissue Sarcomas (STS): Geis-20 Study

Annals of Oncology ◽

10.1016/s0923-7534(20)34065-5 ◽

2012 ◽

Vol 23 ◽

pp. ix490 ◽

Author(s):

J. Martin Broto ◽

X. Garcia Del Muro ◽

A. Lopez-Pousa ◽

R. Las De Penas ◽

J. Maurel ◽

...

Keyword(s):

Clinical Trial ◽

Soft Tissue ◽

Phase Ii ◽

Soft Tissue Sarcomas ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

Prospective Phase ◽

First Line Treatment

Download Full-text

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.9033 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9033-9033

Author(s):

A. Lopez-Pousa ◽

J. Buesa ◽

A. Casado ◽

J. Garcia Del Muro ◽

A. Poveda ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Phase Ii Trial ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Prolonged Infusion ◽

First Line Treatment

Download Full-text

A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10072 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10072-10072 ◽

Author(s):

A. Lopez-Pousa ◽

B. Bui Nguyen ◽

X. Garcia del Muro ◽

J. Martin Broto ◽

C. Balañá ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

New Formulation ◽

First Line Treatment

Download Full-text

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30622-8 ◽

2017 ◽

Vol 18 (10) ◽

pp. 1397-1410 ◽

Author(s):

Beatrice Seddon ◽

Sandra J Strauss ◽

Jeremy Whelan ◽

Michael Leahy ◽

Penella J Woll ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Phase 3 ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Retrospective clinical analysis of MAID protocol as first-line treatment on 137 metastatic soft-tissue sarcomas patients

The Chinese-German Journal of Clinical Oncology ◽

10.1007/s10330-011-0887-3 ◽

2012 ◽

Vol 11 (2) ◽

pp. 117-120 ◽

Author(s):

Kun Han ◽

Yuanjue Sun ◽

Jianjun Zhang ◽

Lina Tang ◽

Shui’er Zheng ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Clinical Analysis ◽

Line Treatment ◽

First Line Treatment

Download Full-text

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

European Journal of Cancer ◽

10.1016/j.ejca.2011.12.008 ◽

2012 ◽

Vol 48 (4) ◽

pp. 547-563 ◽

Author(s):

George D. Demetri ◽

Axel Le Cesne ◽

Sant P. Chawla ◽

Thomas Brodowicz ◽

Robert G. Maki ◽

...

Keyword(s):

Soft Tissue ◽

Phase I ◽

Locally Advanced ◽

Soft Tissue Sarcomas ◽

Double Blind Study ◽

Line Treatment ◽

Double Blind ◽

First Line Treatment

Download Full-text

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.9033 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9033-9033 ◽

Author(s):

A. Lopez-Pousa ◽

J. Buesa ◽

A. Casado ◽

J. Garcia Del Muro ◽

A. Poveda ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Phase Ii Trial ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Prolonged Infusion ◽

First Line Treatment

Download Full-text

Trabectedin [Ecteinascidin 743, ET 743]* "shows promise" as a first-line treatment of soft tissue sarcomas,

Inpharma Weekly ◽

10.2165/00128413-200515030-00018 ◽

2005 ◽

Vol &NA; (1503) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Ecteinascidin 743 ◽

First Line Treatment

Download Full-text

GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.10500 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 10500-10500 ◽

Author(s):

Beatrice M. Seddon ◽

Jeremy Whelan ◽

Sandra J Strauss ◽

Michael Gordon Leahy ◽

Penella J. Woll ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text